Advances in molecular profiling and categorisation of pancreatic adenocarcinoma and the implications for therapy.
Name:
cancers-10-00017.pdf
Size:
447.3Kb
Format:
PDF
Description:
Open access full text article
Affiliation
Division of Cancer Sciences, University of Manchester, Manchester M13 9NT, UKIssue Date
2018-01-12
Metadata
Show full item recordAbstract
Pancreatic ductal adenocarcinoma (PDAC) continues to be a disease with poor outcomes and short-lived treatment responses. New information is emerging from genome sequencing identifying potential subgroups based on somatic and germline mutations. A variety of different mutations and mutational signatures have been identified; the driver mutation in around 93% of PDAC is KRAS, with other recorded alterations being SMAD4 and CDKN2A. Mutations in the deoxyribonucleic acid (DNA) damage repair pathway have also been investigated in PDAC and multiple clinical trials are ongoing with DNA-damaging agents. Rare mutations in BRAF and microsatellite instability (MSI) have been reported in about 1-3% of patients with PDAC, and agents used in other cancers to target these have also shown some promise. Immunotherapy is a developing field, but has failed to demonstrate benefits in PDAC to date. While many trials have failed to improve outcomes in this deadly disease, there is optimism that by developing a better understanding of the translational aspects of this cancer, future informed therapeutic strategies may prove more successful.Citation
Advances in molecular profiling and categorisation of pancreatic adenocarcinoma and the implications for therapy. 2018, 10 (1) CancersJournal
CancersDOI
10.3390/cancers10010017PubMed ID
29329208Type
ArticleLanguage
enISSN
2072-6694ae974a485f413a2113503eed53cd6c53
10.3390/cancers10010017
Scopus Count
Collections
Related articles
- Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma.
- Authors: Qian Y, Gong Y, Fan Z, Luo G, Huang Q, Deng S, Cheng H, Jin K, Ni Q, Yu X, Liu C
- Issue date: 2020 Oct 2
- Genetic Testing in Pancreatic Ductal Adenocarcinoma: Implications for Prevention and Treatment.
- Authors: Peters ML, Tseng JF, Miksad RA
- Issue date: 2016 Jul
- Genomic Profiling and Potentially Targetable Alterations in Pancreatic Ductal Adenocarcinoma.
- Authors: Gleeson FC, Levy MJ
- Issue date: 2018 Dec
- Molecular Characterization of KRAS Wild-type Tumors in Patients with Pancreatic Adenocarcinoma.
- Authors: Philip PA, Azar I, Xiu J, Hall MJ, Hendifar AE, Lou E, Hwang JJ, Gong J, Feldman R, Ellis M, Stafford P, Spetzler D, Khushman MM, Sohal D, Lockhart AC, Weinberg BA, El-Deiry WS, Marshall J, Shields AF, Korn WM
- Issue date: 2022 Jun 13
- The germline/somatic DNA damage repair gene mutations modulate the therapeutic response in Chinese patients with advanced pancreatic ductal adenocarcinoma.
- Authors: Shui L, Li X, Peng Y, Tian J, Li S, He D, Li A, Tian B, Li M, Gao H, An N, Yi C, Cao D
- Issue date: 2021 Jul 12